

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Immunotech Biopharm Ltd**

**永泰生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6978)**

### **POSTPONEMENT OF BOARD MEETING**

Reference is made to the announcement of Immunotech Biopharm Ltd (the “**Company**”) dated 13 March 2025, in relation to the meeting of the board of directors (the “**Board**”) of the Company to be held on Friday, 28 March 2025, for the purpose of, among other matters, approving the publication of the announcement of the annual results of the Company and its subsidiaries for the year ended 31 December 2024 (the “**2024 Annual Results**”).

As additional time is required to finalise the 2024 Annual Results, the Board hereby announces that the abovementioned Board meeting will be postponed to Monday, 31 March 2025.

By order of the Board  
**Immunotech Biopharm Ltd**  
**Tan Zheng**  
*Chairman and executive Director*

Hong Kong, 24 March 2025

*As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu as executive Director, Mr Tao Ran, Mr Wang Ruihua, Mr Yang Fan and Mr Wang Donghu as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.*